Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (52 quarters reported)
$144M in Q3 2013 → $529M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Abivax Sa Call | 10.1% | New | 400,000 | $53.3M |
| Vor Biopharma Inc | 5.9% | Trimmed 2.9% | 1,700,000 | $31.3M |
| Abivax Sa | 5.1% | New | 204,314 | $27.2M |
| Immunitybio Inc Put | 5.0% | Unchanged | 3,000,800 | $26.3M |
| Vera Therapeutics Inc | 4.9% | Added 201% | 600,836 | $25.8M |
| Zura Bio Ltd | 4.7% | Unchanged | 4,215,930 | $24.9M |
| Alumis Inc | 4.6% | Unchanged | 856,061 | $24.1M |
| Sol-gel Technologies Ltd | 3.8% | Unchanged | 274,363 | $20.3M |
| UP Ultragenyx Pharmaceutical In Put | 3.8% | New | 600,000 | $20M |
| Definium Therapeutics Inc | 3.8% | New | 425,000 | $20M |
| Annexon Inc | 3.8% | Added 40% | 3,500,000 | $20M |
| Oruka Therapeutics Inc | 3.3% | Unchanged | 183,330 | $17.4M |
| Moonlake Immunotherapeutics | 3.1% | Added 71% | 855,813 | $16.7M |
| Sagimet Biosciences Inc | 3.0% | New | 2,029,933 | $15.7M |
| Contineum Therapeutics Inc | 2.9% | Added 15% | 921,481 | $15.1M |
| Immix Biopharma Inc | 2.5% | Added 265% | 1,277,642 | $13.2M |
| Climb Bio Inc | 2.5% | Trimmed 25% | 1,000,000 | $13M |
| Amylyx Pharmaceuticals Inc | 2.4% | Trimmed 60% | 700,000 | $12.6M |
| Nektar Therapeutics | 2.3% | Trimmed 45% | 175,000 | $12.2M |
| Neurogene Inc | 2.1% | Trimmed 30% | 352,180 | $11.1M |
| Lb Pharmaceuticals Inc | 1.9% | Added 5.7% | 317,221 | $10.3M |
| Opus Genetics Inc | 1.5% | Added 507% | 1,970,187 | $8.1M |
| Eupraxia Pharmaceuticals Inc | 1.5% | Unchanged | 1,200,000 | $7.93M |
| Bright Minds Biosciences Inc | 1.5% | Trimmed 50% | 109,603 | $7.69M |
| Inflarx Nv | 1.3% | New | 3,046,557 | $6.82M |
| Relmada Therapeutics Inc | 1.1% | Unchanged | 842,106 | $5.83M |
| Jatt Ii Acquisition Corp | 1.1% | New | 500,000 | $5.68M |
| Cullinan Therapeutics Inc | 1.0% | Unchanged | 300,000 | $5.46M |
| Altimmune Inc | 1.0% | New | 1,741,232 | $5.29M |
| Amanat Acquisition Corp | 1.0% | New | 500,000 | $5.08M |
| Rezolute Inc | 0.9% | Unchanged | 951,809 | $4.95M |
| Silence Therapeutics PLC | 0.9% | Trimmed 56% | 450,000 | $4.94M |
| Palisade Bio Inc | 0.9% | Trimmed 33% | 2,284,819 | $4.78M |
| Evommune Inc | 0.8% | Unchanged | 325,000 | $4.32M |
| Scynexis Inc | 0.7% | New | 944,292 | $3.84M |
| Galectin Therapeutics Inc Call | 0.7% | Unchanged | 800,000 | $3.71M |
| Enliven Therapeutics Inc | 0.7% | New | 70,000 | $3.55M |
| Humacyte Inc | 0.6% | Unchanged | 3,750,000 | $2.93M |
| Rein Therapeutics Inc | 0.5% | New | 2,575,000 | $2.68M |
| DT Dbv Technologies S A | 0.5% | New | 156,906 | $2.57M |
| Anavex Life Sciences Corp Call | 0.3% | Unchanged | 521,300 | $1.35M |
| Promis Neurosciences Inc | 0.2% | Trimmed 77% | 86,150 | $1.13M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abivax Sa | New | +400,000 | +$53.3M | 10.1% |
| Apogee Therapeutics Inc | Exited | −374,000 | −$31.5M | — |
| Abivax Sa | New | +204,314 | +$27.2M | 5.1% |
| UP Ultragenyx Pharmaceutical In | New | +600,000 | +$20M | 3.8% |
| Definium Therapeutics Inc | New | +425,000 | +$20M | 3.8% |
| Amylyx Pharmaceuticals Inc | Trimmed | −1,050,000 | −$18.9M | 2.4% |
| Vera Therapeutics Inc | Added | +401,488 | +$17.2M | 4.9% |
| Sagimet Biosciences Inc | New | +2,029,933 | +$15.7M | 3.0% |
| Kalvista Pharmaceuticals Inc | Exited | −675,000 | −$13.6M | — |
| Immunovant Inc | Exited | −545,625 | −$13.6M | — |
Showing the 10 largest of 42 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Immunitybio Inc | New | +3,000,800 | +$23M | 5.3% |
| Sol-gel Technologies Ltd | New | +274,363 | +$21.7M | 5.0% |
| Disc Medicine Inc | Exited | −250,000 | −$19.9M | — |
| Rapt Therapeutics Inc | Exited | −581,187 | −$19.7M | — |
| Alumis Inc | New | +856,061 | +$18.9M | 4.3% |
| Soleno Therapeutics Inc | Exited | −400,000 | −$18.5M | — |
| Bright Minds Biosciences Inc | New | +220,000 | +$16.1M | 3.7% |
| Dianthus Therapeutics Inc | Exited | −350,000 | −$14.4M | — |
| Annexon Inc | New | +2,500,000 | +$13.9M | 3.2% |
| Zenas Biopharma Inc | New | +524,066 | +$10.2M | 2.4% |
Showing the 10 largest of 41 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Disc Medicine Inc | New | +250,000 | +$19.9M | 6.4% |
| Rapt Therapeutics Inc | New | +581,187 | +$19.7M | 6.4% |
| Vor Biopharma Inc | New | +1,370,107 | +$17.9M | 5.8% |
| AP Ascendis Pharma A/s Sponsored ADR | Exited | −75,000 | −$14.9M | — |
| AS Abivax Sa Sponsored Ads | Exited | −150,000 | −$12.7M | — |
| Kalvista Pharmaceuticals Inc | New | +685,632 | +$11.1M | 3.6% |
| Contineum Therapeutics Inc | New | +800,000 | +$9.14M | 3.0% |
| Fulcrum Therapeutics Inc | New | +800,000 | +$9.05M | 2.9% |
| CC Cytokinetics Inc Com New | Exited | −150,000 | −$8.24M | — |
| Soleno Therapeutics Inc | Added | +175,000 | +$8.1M | 6.0% |
Showing the 10 largest of 35 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AS Abivax Sa Sponsored Ads | Trimmed | −1,141,617 | −$96.9M | 5.3% |
| Ionis Pharmaceuticals Inc | Trimmed | −420,000 | −$27.5M | 2.2% |
| NT Nektar Therapeutics Com New | New | +300,000 | +$17.1M | 7.0% |
| Soleno Therapeutics Inc | New | +225,000 | +$15.2M | 6.3% |
| AP Ascendis Pharma A/s Sponsored ADR | New | +75,000 | +$14.9M | 6.1% |
| Apogee Therapeutics Inc | New | +304,000 | +$12.1M | 5.0% |
| Dianthus Therapeutics Inc | New | +265,803 | +$10.5M | 4.3% |
| LB Legend Biotech Corp Sponsored Ads | Trimmed | −236,540 | −$7.71M | 1.5% |
| Akebia Therapeutics Inc | Exited | −1,985,915 | −$7.23M | — |
| Eupraxia Pharmaceuticals Inc | New | +1,200,000 | +$7.08M | 2.9% |
Showing the 10 largest of 30 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Akebia Therapeutics Inc | Trimmed | −2,987,925 | −$10.9M | 4.7% |
| Viridian Therapeutics Inc | Exited | −750,000 | −$10.1M | — |
| Merus N V | Exited | −237,156 | −$9.98M | — |
| Ionis Pharmaceuticals Inc | Added | +250,000 | +$9.88M | 12.8% |
| Rezolute Inc | Added | +2,200,420 | +$9.81M | 8.8% |
| Kalvista Pharmaceuticals Inc | Trimmed | −691,197 | −$7.81M | 2.4% |
| Ascendis Pharma A/s | Exited | −50,000 | −$7.79M | — |
| Dynavax Technologies Corp | Exited | −595,879 | −$7.73M | — |
| Legend Biotech Corp | Added | +211,760 | +$7.52M | 8.1% |
| Cytokinetics Inc | Trimmed | −220,000 | −$7.27M | 3.2% |
Showing the 10 largest of 33 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Akebia Therapeutics Inc | New | +4,973,840 | +$9.55M | 5.1% |
| Kalvista Pharmaceuticals Inc | Trimmed | −772,636 | −$8.92M | 6.2% |
| Ascendis Pharma A/s | New | +50,000 | +$7.79M | 4.1% |
| Ionis Pharmaceuticals Inc | Trimmed | −255,007 | −$7.69M | 4.0% |
| Jasper Therapeutics Inc | Exited | −322,380 | −$6.89M | — |
| Amylyx Pharmaceuticals Inc | New | +1,811,996 | +$6.41M | 3.4% |
| Immunovant Inc | New | +375,000 | +$6.41M | 3.4% |
| Summit Therapeutics Inc | New | +250,000 | +$4.82M | 2.6% |
| Legend Biotech Corp | New | +138,240 | +$4.69M | 2.5% |
| Oruka Therapeutics Inc | Exited | −228,803 | −$4.44M | — |
Showing the 10 largest of 28 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Neurogene Inc | Trimmed | −561,530 | −$12.8M | 4.8% |
| Olema Pharmaceuticals Inc | Exited | −1,000,000 | −$11.9M | — |
| Pliant Therapeutics Inc | Trimmed | −855,121 | −$11.3M | 6.5% |
| Xenon Pharmaceuticals Inc | New | +245,272 | +$9.61M | 4.5% |
| Ionis Pharmaceuticals Inc | Added | +250,007 | +$8.74M | 8.3% |
| Optinose Inc | Exited | −12,861,136 | −$8.62M | — |
| Arcellx Inc | Exited | −100,000 | −$8.35M | — |
| Arcellx Inc | Exited | −100,000 | −$8.35M | — |
| Outlook Therapeutics Inc | Exited | −1,293,028 | −$6.9M | — |
| Urogen Pharma Ltd | Trimmed | −570,943 | −$6.08M | 0.9% |
Showing the 10 largest of 31 changes.
quarter ended September 30, 2024 · filed November 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Arcellx Inc | Trimmed | −392,000 | −$32.7M | 2.5% |
| Urogen Pharma Ltd | Trimmed | −2,147,473 | −$27.3M | 2.8% |
| Evolus Inc | Trimmed | −1,281,772 | −$20.8M | 5.6% |
| Insmed Inc | Exited | −250,000 | −$16.8M | — |
| Amicus Therapeutics Inc | Exited | −1,495,500 | −$14.8M | — |
| Merus N V | Trimmed | −273,288 | −$13.7M | 3.7% |
| Dianthus Therapeutics Inc | Trimmed | −482,929 | −$13.2M | 2.2% |
| ET Esperion Therapeutics Inc Ne | Exited | −5,791,594 | −$12.9M | — |
| Oruka Therapeutics Inc | New | +514,659 | +$12.6M | 3.7% |
| Dynavax Technologies Corp | Trimmed | −1,047,766 | −$11.7M | 4.3% |
Showing the 10 largest of 37 changes.
Loading...
